Praxis Precision Medicines, Inc. Common Stock
PRAXPraxis Precision Medicines, Inc. (PRAX) is a biotechnology company focused on developing targeted therapies for neuroscience and rare diseases. The company leverages precision medicine approaches to create treatments tailored to specific genetic and molecular profiles, aiming to improve outcomes for patients with neurological and neuropsychiatric conditions.
Company News
Praxis Precision Medicines announced strategic leadership changes to support its transition into late-stage development and commercial execution. The company appointed Jeffrey B. Kindler (former Pfizer CEO) and Stuart Arbuckle (former Vertex COO) to its board of directors, and promoted Megan Sniecinski to Chief Operating Officer and Dr. Steven Pe...
Praxis Precision Medicines priced an underwritten public offering of 2.212 million shares at $260 per share, generating approximately $575 million in gross proceeds. The offering is expected to close on January 8, 2026, with underwriters granted a 30-day option to purchase an additional 331,800 shares. The company is a clinical-stage biopharmaceu...
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, announced a proposed public offering of common stock and pre-funded warrants. The offering is being managed by Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities as joint book-running managers, with completion subject...
Praxis Precision Medicines stock surged 13.25% after receiving FDA Breakthrough Therapy Designation for ulixacaltamide, an experimental treatment for essential tremor. The designation, based on positive phase 3 study results, will accelerate the drug's development and regulatory review, with a New Drug Application planned for early 2026. Essentia...
Praxis Precision Medicines received FDA Breakthrough Therapy Designation for ulixacaltamide, a T-type calcium channel inhibitor for essential tremor treatment, based on positive Phase 3 Essential3 program results. The company plans to submit a New Drug Application (NDA) in early 2026 following a successful pre-NDA meeting with the FDA.
